Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases. (21st December 2018)

• Record Type: Journal Article
• Authors: Holtze, Colin; Flaherty, Kevin; Kreuter, Michael; Luppi, Fabrizio; Moua, Teng; Vancheri, Carlo; Scholand, Mary B.
• Is Part Of: European respiratory review. Volume 27:Number 150(2018)
• Publication Date: 2018-12-21
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiratory Tract Diseases; Respiratory organs -- Diseases; Respiratory organs -- Diseases -- Treatment; Electronic journals; Periodical; Periodicals; Periodicals; 616.2
• DOI: 10.1183/16000617.0078-2018
• Languages: English
• ISSNs: 0905-9180

Abstract

There are over 200 interstitial lung diseases (ILDs). In addition to patients with idiopathic pulmonary fibrosis (IPF), a percentage of patients with other ILDs also develop progressive fibrosis of the lung during their disease course. Patients with progressive-fibrosing ILDs may show limited response to immunomodulatory therapy, worsening symptoms and lung function and, ultimately, early mortality. There are few data for ILDs that may present a progressive fibrosing phenotype specifically, but we believe the burden and healthcare costs associated with these conditions may be comparable to those reported in IPF. This review discusses the burden of ILDs that may present a progressive fibrosing phenotype and the factors impacting healthcare utilisation. Data for ILDs with a progressive fibrosing phenotype are lacking, but the burden and healthcare costs associated with these conditions may be comparable to those reported in IPF http://ow.ly/Eoht30mS4Nx